Login to Your Account



Pharma: Clinic Roundup


Thursday, June 28, 2012
• CSL Behring, of King of Prussia, Pa., reported data from a single-arm, open-label study showing that Privagen (immune globulin intravenous [human], 10 percent liquid), an intravenous immunoglobulin (IVIG), may lead to improvement in function in patients with chronic inflammatory demyelinating polyneuropathy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription